bluuebunny/crossref_metadata_2025_split huggingface dataset:
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
Authors: Zhang Peiling , Yang Xiuxiu , Cao Yang , Wang Jue , Zhou Mi , Chen Liting , Wei Jia , Mao Zekai , Wang Di , Xiao Yi , Zhu Haichuan , Zhang Shangkun , Zhang Tongcun , Zhang Yicheng , Zhou Jianfeng , Huang Liang 
Published: October 2022

Abstract
Background
Long-term outcome is unfavourable for relapsed/refractory (r/r) lymphoma patients who are resistant to salvage chemotherapy, even after subsequent autologous stem-cell transplantation (ASCT). Although anti-CD30 chimeric antigen receptor (CAR30) T-cell therapy induces high response rates in these patients, the duration of response is relatively limited.

Methods
This open-label, single-center and single-arm pilot study investigated the safety and efficacy of ASCT in tandem with CAR30 T-cell infusion in r/r CD30+ lymphoma. The primary endpoint was safety and key secondary endpoint was overall response rate, overall survival, progression-free survival, and duration of response.

Results
Five classical Hodgkin lymphoma (cHL) patients and 1 anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) patient were enrolled. The median age was 24 years. No patient had prior ASCT. Three patients (50.0%) relapsed for ≥ 2 times and 3 patients (50.0%) had primary refractory diseases. All had a Deauville score of 4 or 5, and 5 patients (83.3%) had a stable or progressive disease (SD/PD) at enrollment. All patients received myeloablative chemotherapy and infused CD34-positive hematopoietic stem cells (HSCs) and CAR30 T cells in tandem, with a median dose of 3.9 × 106/kg and 7.6 × 106/kg, respectively. Five paitents presented with cytokine release syndrome (CRS), all of which were grade 1. No neurotoxicity was observed. All patients had successful HSCs engraftment and reached an objective response, including 5 (4 cHL and 1 ALCL, 83.3%) with a complete response (CR) and 1 with a partial response (PR). With a median follow-up of 20.4 (range, 12.1–34.4) months, all remained alive and maintained their responses.

Conclusion
Our work demonstrates the combined administration of ASCT and CAR30 T-cell therapy is well-tolerate and highly effective in r/r cHL and ALCL, even in PET-positive or chemorefractory patients who are expected to have inferior outcome after ASCT, although further large-scaled validation in prospective clinical trial is warranted.
Trial registration The trial was registered with the Chinese Clinical Trial Registry (ChiCTR, number ChiCTR2100053662).
Particle size distributions inside and around the artificial crater produced by the Hayabusa2 impact experiment on Ryugu
Authors: Ogawa K. , Sakatani N. , Kadono T. , Arakawa M. , Honda R. , Wada K. , Shirai K. , Shimaki Y. , Ishibashi K. , Yokota Y. , Saiki T. , Imamura H. , Tsuda Y. , Nakazawa S. , Takagi Y. , Hayakawa M. , Yano H. , Okamoto C. , Iijima Y. , Morota T. , Kameda S. , Tatsumi E. , Cho Y. , Yoshioka K. , Sawada H. , Matsuoka M. , Yamada M. , Kouyama T. , Suzuki H. , Honda C. , Sugita S. 
Published: October 2022

AbstractJapanese Hayabusa2 spacecraft has successfully carried out an impact experiment using a small carry-on impactor (SCI) on an asteroid (162173) Ryugu. We examine the size distribution of particles inside and outside an artificial impact crater (the SCI crater) based on the images taken by the optical navigation camera onboard the Hayabusa2 spacecraft. The circumferential variation in particle size distribution inside the SCI crater is recognized and we interpret that major circumferential variation is caused by the large boulders inside the SCI crater that existed prior to the impact. The size distribution inside the SCI crater also shows that the subsurface layer beneath the SCI impact site had a large number of particles with a characteristic size of – 9 cm, which is consistent with the previous evaluations. On the other hand, the size distribution outside the SCI crater exhibits the radial variation, implying that the deposition of ejecta from the SCI crater is involved. The slope of the size distribution outside the crater at small sizes differs from the slope of the size distribution on the surface of Ryugu by approximately 1 or slightly less. This is consistent with the claim that some particles are buried in fine particles of the subsurface origin included in ejecta from the SCI crater. Thus, the particle size distributions inside and outside the SCI crater reveal that the subsurface layer beneath the SCI impact site is rich in fine particles with – 9 cm in size while the particles on the surface have a size distribution of a power-law form with shallower slopes at small sizes due to the deposition of fine ejecta from the subsurface layer. Finally, we discuss a process responsible for this difference in particle size distribution between the surface and the subsurface layers. The occurrence of segregation in the gravitational flow of particles on the surface of Ryugu is plausible.
Graphical Abstract
Multimodality treatment for brain arteriovenous malformation in Mainland China: design, rationale, and baseline patient characteristics of a nationwide multicenter prospective registry
Authors: Chen Yu , Han Heze , Ma Li , Li Ruinan , Li Zhipeng , Yan Debin , Zhang Haibin , Yuan Kexin , Wang Ke , Zhao Yang , Zhang Yukun , Jin Weitao , Li Runting , Lin Fa , Meng Xiangyu , Hao Qiang , Wang Hao , Ye Xun , Kang Shuai , Jin Hengwei , Li Youxiang , Gao Dezhi , Sun Shibin , Liu Ali , Wang Shuo , Chen Xiaolin , Zhao Yuanli 
Published: October 2022

Abstract
Background
Brain arteriovenous malformation (AVM) is an important cause of hemorrhagic stroke in young adults, which can lead to severe neurological impairment. The registry of Multimodality treatment for brain ArTeriovenous malformation in mainland CHina (MATCH) is a national prospective registry to identify the natural history of AVMs in Asian population; to investigate traditional and emerging hemorrhagic predictors; and to explore the superiority of the multidisciplinary assessment in improving the long-term outcomes.

Methods
Consecutive AVM patients will be enrolled from 52 participating hospitals in mainland China. Baseline demographic, clinical and imaging data will be collected prospectively. Conservation, microsurgery, embolization, stereotactic radiosurgery (SRS), and multimodal strategies are all included in this study. Patients will be divided into experimental and control group according to whether the treatment protocols are formulated by multidisciplinary team. Neurofunctional status, subsequent hemorrhage, seizure, and novel neurofunctional deficit will be queried at 3 months, annually (1 and 2 years), 3 years, and 10 years follow-up.

Results
Between August 2011 and April 2021, 3241 AVMs were enrolled in 11 participating sites. Among them, 59.0% were male with an average age of 28.4 ± 14.6 years, 61.2% had rupture history and 2268 hemorrhagic events occurred before admission. The median Spetzler-Martin grade and Lawton-Young grade was 3 and 5, respectively. Microsurgery is the dominant strategy (35.7%), with a similar proportion of embolization, SRS, and a combination of both (12.7%; 14.8%; 11.8%; respectively). Among them, 15.43% underwent multidisciplinary assessment and received standardized treatment. At the most recent follow-up, 7.8% were lost and the median follow-up duration was 5.6 years.

Conclusions
The MATCH study is a large-sample nationwide prospective registry to investigate multimodality management strategy for AVMs. Data from this registry may also provide the opportunity for individualized risk assessment and the development of optimal individual management strategies.

Trial registration
ClinicalTrials.gov Registry (NCT04572568).
Role of magnetic resonance imaging in evaluation of ejaculatory duct in Zinner’s syndrome: case series of five patients and review of the literature
Authors: Elsorougy Ali , Farg Hashim , Badawy Mohamed , Shebel Haytham , El-Ghar Mohamed Abou , Abdelhamid Abdalla 
Published: October 2022

Abstract
Background
Zinner's syndrome is a mesonephric duct anomaly characterized by unilateral renal agenesis, ipsilateral seminal vesicle cyst, and ipsilateral ejaculatory duct obstruction due to insult occurred at urogenital tract embryogenesis during the first trimester. In the third and fourth decades of life, it is frequently diagnosed when patients begin to be symptomatic, such as lower urinary tract symptoms, infertility and painful ejaculation.

Case presentation
Herein we illustrate case review including five patients diagnosed as Zinner’s syndrome, three of them complaining from infertility; however, the remaining two cases were fertile and incidentally diagnosed.

Conclusions
Radiological investigations play significant role in the diagnostic and management processes including US, CT and MRI for detecting ipsilateral renal agenesis and unilateral seminal vesicles dilatation, but evaluation of ejaculatory duct can be done only by MRI and transrectal ultrasound; however, the latter may be sometimes nonconclusive or intolerable by patients, so MRI is considered the golden modality with its high capability to assess the lower male genital tract which played a significant role in our case series starting with detection of the presence or absence of the ejaculatory duct obstruction as well as the high delineation of the origin and nature the seminal vesicle cyst including also its size and content and finally by detection of the communication between ureteral bud and the seminal vesicles cystic dilatation.
Revealing the output power potential of bifacial monolithic all-perovskite tandem solar cells
Authors: Li Hongjiang , Wang Yurui , Gao Han , Zhang Mei , Lin Renxing , Wu Pu , Xiao Ke , Tan Hairen 
Published: October 2022

AbstractBifacial monolithic all-perovskite tandem solar cells have the promise of delivering higher output power density by inheriting the advantages of both tandem and bifacial architectures simultaneously. Herein, we demonstrate, for the first time, the bifacial monolithic all-perovskite tandem solar cells and reveal their output power potential. The bifacial tandems are realized by replacing the rear metal electrodes of monofacial tandems with transparent conduction oxide electrodes. Bandgap engineering is deployed to achieve current matching under various rear illumination conditions. The bifacial tandems show a high output power density of 28.51 mW cm−2 under a realistic rear illumination (30 mW cm− 2). Further energy yield calculation shows substantial energy yield gain for bifacial tandems compared with the monofacial tandems under various ground albedo for different climatic conditions. This work provides a new device architecture for higher output power for all-perovskite tandem solar cells under real-world conditions.
Ten Steps to Design a Counseling App to Reduce the Psychosocial Impact of Human Papillomavirus Testing on the Basis of a User-Centered Design Approach in a Low- and Middle-Income Setting
Authors: Sánchez Antelo Victoria , Szwarc Lucila , Le Pera Anabella , Fredjkes Paula , Saimovici Diana , Massaccesi Silvia , Paolino Melisa , Viswanath Kasisomayajula , Arrossi Silvina 
Published: October 2022

PURPOSE This study describes the 10 steps followed to produce the information architecture of a user-centered design (UCD) counseling mobile application, the first phase to develop an app. The app aims to reduce the psychosocial impact of the human papillomavirus test result and improve women's knowledge of human papilloma virus and cervical cancer. METHODS We used a UCD approach to produce the information architecture of the app (ie, how to organize contents into features). We analyzed field notes, meeting agendas, and documentation produced during each stage of the design process. We described the goals, methods, and outcomes of each step. We also discussed the critical challenges and the strategies to address them. RESULTS The steps are (1) knowledge, attitudes, and beliefs mapping: reanalysis of team's research findings from prior studies; (2) environmental scanning of apps available on the market; (3) stakeholders' point of view: The International Advisory Committee; (4) potential user's profile: building archetypes through the Persona method; (5) women's interviews: user's preferences and experiences; (6) effective features: scoping review to select app's features that address psychosocial impact; (7) the user journey: ideal interaction with the gynecological service and the counseling app; (8) women's focus groups: using Personas and Scenarios to discuss app's mock-up; (9) women's design sessions: prototype test and card-sorting techniques; and (10) team's design session: translating results into visual objects and features. CONCLUSION We provide here detailed descriptions of the UCD process of an app for human papillomavirus–tested women for those venturing into the area of mHealth strategies work. Our experience can be used as a guide for future mHealth app development for a low- and middle-income setting.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Authors: You Benoit , Purdy Christopher , Copeland Larry J. , Swisher Elizabeth M. , Bookman Michael A. , Fleming Gini , Coleman Robert , Randall Leslie M. , Tewari Krishnansu S. , Monk Bradley J. , Mannel Robert S. , Walker Joan L. , Cappuccini Fabio , Cohn David , Muzaffar Mahvish , Mutch David , Wahner-Hendrickson Andrea , Martin Lainie , Colomban Olivier , Burger Robert A. 
Published: October 2022

PURPOSE In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was a predictive biomarker. Only the patients with high-risk disease (suboptimally resected stage III, or stage IV) exhibiting unfavorable KELIM score < 1.0 had overall survival (OS) benefit from bevacizumab (median: 29.7 v 20.6 months; hazard ratio [HR], 0.78). An external validation study in the GOG-0218 trial was performed. METHODS In GOG-0218, 1,873 patients were treated with carboplatin-paclitaxel ± concurrent-maintenance bevacizumab/placebo. Patient KELIM values were calculated with CA-125 kinetics during the first 100 chemotherapy days by the Lyon University team. The association between KELIM score (favorable ≥ 1.0, or unfavorable < 1.0) and bevacizumab benefit for progression-free survival (PFS)/OS was independently assessed by NGR-GOG using univariate/multivariate analyses. RESULTS KELIM was assessable in 1,662 patients with ≥ 3 CA-125 available values. An unfavorable KELIM score was associated with bevacizumab benefit compared with placebo (PFS: HR, 0.70; 95% CI, 0.59 to 0.82; OS: HR, 0.87; 95% CI, 0.73 to 1.03), whereas a favorable KELIM was not (PFS: HR, 0.96; 95% CI, 0.79 to 1.17; OS: HR, 1.11; 95% CI, 0.89 to 1.39). The highest benefit was observed in patients with a high-risk disease exhibiting unfavorable KELIM, for PFS (median: 9.1 v 5.6 months; HR, 0.64; 95% CI, 0.53 to 0.78), and for OS (median: 35.1 v 29.1 months; HR, 0.79; 95% CI, 0.65 to 0.97). CONCLUSION This GOG-0218 trial investigation validates ICON-7 findings about the association between poor tumor chemosensitivity and benefit from concurrent-maintenance bevacizumab, suggesting that bevacizumab may mainly be effective in patients with poorly chemosensitive disease. Bevacizumab may be prioritized in patients with a high-risk and poorly chemosensitive disease to improve their PFS/OS (patient KELIM score calculator available on the Biomarker Kinetics website).
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Authors: Morris Van K. , Kennedy Erin B. , Baxter Nancy N. , Benson Al B. , Cercek Andrea , Cho May , Ciombor Kristen K. , Cremolini Chiara , Davis Anjee , Deming Dustin A. , Fakih Marwan G. , Gholami Sepideh , Hong Theodore S. , Jaiyesimi Ishmael , Klute Kelsey , Lieu Christopher , Sanoff Hanna , Strickler John H. , White Sarah , Willis Jason A. , Eng Cathy 
Published: October 2022

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria. RECOMMENDATIONS Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti–vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti–epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti–vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E–mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .
Drug-Carrier Miscibility in Solid Dispersions of Glibenclamide and a Novel Approach to Enhance Its Solubility Using an Effervescent Agent
Authors: Pisay Muralidhar , Bhaskar K. Vijaya , Mehta Chetan Hasmukh , Nayak Usha Yogendra , Koteshwara Kunnatur Balasundara , Mutalik Srinivas 
Published: October 2022

AbstractThe present research aims to investigate the miscibility, physical stability, solubility, and dissolution rate of a poorly water-soluble glibenclamide (GLB) in solid dispersions (SDs) with hydrophilic carriers like PEG-1500 and PEG-50 hydrogenated palm glycerides (Acconon). Mathematical theories such as Hansen solubility parameters, Flory Huggins theory, Gibbs free energy, and the in silico molecular dynamics simulation study approaches were used to predict the drug-carrier miscibility. To increase the solubility further, the effervescence technique was introduced to the conventional solid dispersions to prepare effervescent solid dispersions (ESD). Solid dispersions (SDs) were prepared by microwave, solvent evaporation, lyophilization, and hot melt extrusion (HME) techniques and tested for different characterization parameters. The theoretical and in silico parameters suggested that GLB would show good miscibility with the selected carriers under certain conditions. Intermolecular hydrogen bonding between the drug and carrier(s) was confirmed by Fourier transform infrared spectroscopy and proton nuclear magnetic resonance spectroscopy. Solid-state characterizations like powder X-ray diffraction, differential scanning calorimetry, and microscopy confirm the amorphous nature of SDs. The addition of the effervescent agent improved the amorphous nature, due to which the solubility and drug release rate was increased. In vitro and ex vivo intestinal absorption studies showed improved flux and permeability than the pure drug, suggesting an enhanced drug delivery. The GLB solubility, dissolution, and stability were greatly enhanced by the SD and ESD technology.
Graphical Abstract
Albert O. Hirschman, Europe, and the Postwar Economic Order, 1946–52
Authors: Alacevich Michele , Asso Pier Francesco 
Published: October 2022

AbstractBetween 1946 and 1952, Albert Hirschman worked as an economist in charge of the Western European desk of the research branch of the Board of Governors of the Federal Reserve System in Washington, DC. In this position he wrote extensively on patterns of European postwar reconstruction and the creation of a new world economic order. Given his deep knowledge and prewar experiences, Italy and France were his first areas of specialization, although Hirschman soon contributed to the analysis of the Marshall Plan, the shaping of the European Payments Union, and the problem of the dollar shortage. This article provides a comprehensive interpretation of this early stage of Hirschman's intellectual biography, including a discussion of an unpublished proposal for the creation of a new European Monetary Authority developed under the auspices of Paul Hoffman and the Economic Cooperation Administration. In addition to highlighting Hirschman's contributions to several technical aspects of European reconstruction and the restoration of multilateralism, the article shows that during the Fed years, he sharpened his ability to examine processes of policymaking in difficult times. In particular, he rejected prefabricated recipes, developing a sensitivity for inverted sequential processes, inducement mechanisms, and apparently paradoxical solutions in an uncertain environment. This sensitivity is at the basis of what has been described as a distinctively “Hirschmanesque” style of thought.
Comparison of EMG Activity in Leg Muscles between Overground and Treadmill Running
Authors: DARENDELI ABDULKERIM , ERTAN HAYRI , ENOKA ROGER MARO 
Published: October 2022

ABSTRACT

Introduction
Treadmills have been widely used for training and performance testing during which the treadmill grade is usually set to 0%–2% grade. The purpose of our study was to compare the level of activation of lower body muscles when running at two speeds in an overground condition and on a treadmill at 0%, 1%, and 2% grades.

Methods
We recorded EMG data of eight lower body muscles from 13 recreationally active individuals during overground and treadmill running at 2.92 and 4.58 m·s−1. Maximal voluntary contraction (MVC) tests were performed (3 × 6 s) to identify maximal torque and EMG values. The stride cycles, from one foot strike to the next, were identified using a pair of triaxial accelerometers. A two-way repeated-measures ANOVA was used to examine the differences in EMG activity across running conditions and speeds. Cohen’s d effect size was calculated to indicate the difference between the overground and the treadmill running conditions.

Results
The effect sizes were moderate to negligible for differences between the EMG integral values for overground running and the three treadmill grades. The coefficient of variation for stride time during overground running was significantly larger than that of the treadmill running at 4.58 m·s−1.

Conclusions
The results showed that the overall EMG profiles of the thigh and shank muscles were similar for the overground and treadmill conditions, but the similarity was greatest for thigh muscles when running on the treadmill at 1% grade and for shank muscles at 2% grade. The variability in stride time was greater during overground running than when running on a treadmill and was associated with elevated EMG activity of some muscles.